Olanzapine induced neuroleptic malignant syndrome | Zendy

BichitraNanda Patra | Zendy; SudhirK Khandelwal | Zendy; Mamta Sood | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Olanzapine induced neuroleptic malignant syndrome

Author(s) -

BichitraNanda Patra,

SudhirK Khandelwal,

Mamta Sood

Publication year - 2013

Publication title -

indian journal of pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.286

H-Index - 59

eISSN - 1998-3751

pISSN - 0253-7613

DOI - 10.4103/0253-7613.106448

Subject(s) - neuroleptic malignant syndrome , olanzapine , bromocriptine , medicine , antipsychotic , atypical antipsychotic , levodopa , pediatrics , psychiatry , anesthesia , schizophrenia (object oriented programming) , disease , parkinson's disease , prolactin , hormone

An 18 year old male diagnosed as a case of bipolar affective disorder (BPAD), developed neuroleptic malignant syndrome (NMS) following treatment with olanzapine (20 mg per day), an atypical antipsychotic drug. NMS is usually seen with typical antipsychotic drugs. The patient was diagnosed as a case of NMS, offending agent was immediately withdrawn and prompt treatment with bromocriptine and levodopa produced a good recovery. The various features of the case are discussed in view of the potential mortality of the syndrome.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research